(3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide
C79H101N15O17S — CID 171425265
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide
(3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide (PubChem CID 171425265) has the molecular formula C79H101N15O17S and a molecular weight of 1564.83 g/mol. Its IUPAC name is (3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide.
Molecular Properties
| Compound Name | (3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide |
|---|---|
| PubChem CID | 171425265 |
| Molecular Formula | C79H101N15O17S |
| Molecular Weight | 1564.83 g/mol |
| Exact Mass | 1563.72 |
| IUPAC Name | (3R,6S,9S,12S,15S,21S,24S,27S,30S,36S)-N-(2-amino-2-oxoethyl)-9,36-dibenzyl-21-(hydroxymethyl)-12,24-bis[(4-hydroxyphenyl)methyl]-15-(1H-indol-3-ylmethyl)-10-methyl-6,30-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclononatriacontane-3-carboxamide |
| SMILES | CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)CSC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C(C)C)NC1=O |
| InChI | InChI=1S/C79H101N15O17S/c1-44(2)30-56-76(108)93-69(46(5)6)78(110)89-59(33-49-22-26-52(96)27-23-49)74(106)91-62(41-95)71(103)84-40-67(100)86-60(36-51-37-81-55-21-15-14-20-54(51)55)75(107)90-61(34-50-24-28-53(97)29-25-50)79(111)94(7)64(35-48-18-12-9-13-19-48)77(109)88-57(31-45(3)4)73(105)92-63(72(104)82-38-65(80)98)42-112-43-68(101)87-58(32-47-16-10-8-11-17-47)70(102)83-39-66(99)85-56/h8-29,37,44-46,56-64,69,81,95-97H,30-36,38-43H2,1-7H3,(H2,80,98)(H,82,104)(H,83,102)(H,84,103)(H,85,99)(H,86,100)(H,87,101)(H,88,109)(H,89,110)(H,90,107)(H,91,106)(H,92,105)(H,93,108)/t56-,57-,58-,59-,60-,61-,62-,63-,64-,69-/m0/s1 |
| InChIKey | QZRWESMJEZLUHY-KZYKFPDRSA-N |
| XLogP | -0.40 |
| TPSA | 489.08 Ų |
| H-Bond Donors | 17 |
| H-Bond Acceptors | 18 |
| Rotatable Bonds | 19 |
| Heavy Atoms | 112 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1564.83 |
| LogP ≤ 5 | -0.40 |
| H-Bond Donors ≤ 5 | 17 |
| H-Bond Acceptors ≤ 10 | 18 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171425265 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.